Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Flecainide and anti-arrhythmia therapy].

L Croce1, S Romano, L Pozzoni

  • 1Divisione di Cardiologia, Ospedale San Paolo di Milano.

Minerva Medica
|March 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atrial fibrillation among master athletes: A complex relationship.

International journal of cardiology·2026
Same author

Early psychiatric manifestations in pediatric autoimmune encephalitis: clinical data from a tertiary center.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2025
Same author

Measurement of ^{19}F(p, αγ)^{16}O Reaction Reopens the Fluorine Conundrums in Stars.

Physical review letters·2025
Same author

Editorial: Pharmacological therapy in patients with arrhythmias.

Frontiers in pharmacology·2024
Same author

Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro.

Journal of endocrinological investigation·2024
Same author

Experimental Determination of α Widths of ^{21}Ne Levels in the Region of Astrophysical Interest: New ^{17}O+α Reaction Rates and Impact on the Weak s Process.

Physical review letters·2024

Flecainide, a Class IC anti-arrhythmia drug, effectively treats various supraventricular and ventricular arrhythmias, including atrial fibrillation and ventricular ectopias. Its high efficacy and long half-life make it suitable for prolonged treatment, especially for drug-resistant cases.

Area of Science:

  • Pharmacology
  • Cardiology

Context:

  • Flecainide, a Class IC anti-arrhythmia medication, has emerged as a significant therapeutic agent.
  • Its introduction addresses the need for effective treatments for complex cardiac arrhythmias.

Purpose:

  • To review the electrophysiological properties and clinical applications of Flecainide.
  • To highlight its efficacy in treating supraventricular and ventricular arrhythmias.

Summary:

  • Flecainide, a Class IC anti-arrhythmia drug, demonstrates high efficacy (>90%) in treating ventricular ectopias.
  • It is particularly effective for supraventricular arrhythmias such as atrial fibrillation (including in Wolff-Parkinson-White disease), reciprocating supraventricular tachycardias, and focal atrial tachycardias.
  • The drug's favorable pharmacokinetic profile, including good bioavailability and a long half-life, supports its use in long-term management.

Related Experiment Videos

Impact:

  • Flecainide is indicated for both supraventricular and ventricular arrhythmias, especially those resistant to other treatments.
  • Its effectiveness and suitability for prolonged therapy position it for widespread clinical use in arrhythmia management.